NeuroSense Therapeutics (NASDAQ:NRSN) reported positive preliminary results from a novel biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment of Parkinson’s...
Search results for - neurosense
NeuroSense, Mass General to collaborate on PrimeC in ALS
NeuroSense Therapeutics (NASDAQ:NRSN) signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, Ph.D., and Massachusetts General Hospital’s NeuroEpigenetics lab to explore the neurotherapeutic effects of...
NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial
Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...
NeuroSense receives IND clearance for Phase 2b ALS study
The FDA cleared NeuroSense Therapeutics’ (NASDAQ:NRSN) IND for its Phase 2b PARADIGM study with its lead drug candidate, PrimeC, in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling...
NeuroSense, NeuraLight in pact to detect ALS oculometric biomarkers
NeuroSense Therapeutics (NASDAQ:NRSN) and closely-held NeuraLight are collaborating to advance the science of digital biomarkers in the detection and monitoring of neurological diseases, including amyotrophic lateral...
NeuroSense reports positive biomarker study in Alzheimer’s
NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease...
NeuroSense posts positive results from stage 3 ALS biomarker study
NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from stage 3 of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense’s lead combination...
NeuroSense advancing potential paradigm shift in ALS therapy
NeuroSense Therapeutics (NASDAQ:NRSN) is developing a novel fixed dose combination of two FDA-approved drugs for a multi-targeted approach against the potential pathways responsible for ALS, or amyotrophic lateral...
NeuroSense enrolls first patient in Phase 2b ALS Trial with PrimeC
NeuroSense Therapeutics (NASDAQ:NRSN) enrolled the first patient in its Phase 2b PARADIGM trial for its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM will enroll 69...
Maxim starts NeuroSense at buy; PT $7
Maxim Group initiated coverage of NeuroSense Therapeutics (NASDAQ:NRSN) with a “buy” rating and price target of $7. The stock closed at $2.53 on Jan. 6. NeuroSense is a clinical-stage company developing therapies for...
